News
Insights
Jobs
Career Advice
Companies
Hotbeds
More

SUBSCRIBE

SUBSCRIBE

News
Insights
Jobs
Career Advice
Companies
Hotbeds
More

Search Query

Search Results

Looking for jobs? Search jobs

11,100 Results

Type

Article (1293)
Company Profile (4)
Press Release (9803)

Section

Business (3245)
Career Advice (41)
Deals (552)
Drug Delivery (45)
Drug Development (1623)
Employer Resources (4)
FDA (439)
Job Trends (258)
News (5783)
Policy (617)

Tag

Date

Today (3)
Last 7 days (23)
Last 30 days (122)
Last 365 days (1034)
2024 (971)
2023 (763)
2022 (1039)
2021 (978)
2020 (916)
2019 (778)
2018 (594)
2017 (730)
2016 (536)
2015 (551)
2014 (437)
2013 (361)
2012 (395)
2011 (404)
2010 (359)

Location

Africa (20)
Asia (601)
Australia (218)
California (68)
Canada (27)
China (12)
Europe (3022)
Florida (11)
Indiana (12)
Maryland (15)
Massachusetts (53)
Michigan (13)
Minnesota (5)
New Jersey (24)
New York (7)
North Carolina (6)
Northern California (36)
Pennsylvania (18)
South America (18)
Southern California (21)
Texas (7)
Washington State (5)

Filters

Type

Article (1293)
Company Profile (4)
Press Release (9803)

Section

Business (3245)
Career Advice (41)
Deals (552)
Drug Delivery (45)
Drug Development (1623)
Employer Resources (4)
FDA (439)
Job Trends (258)
News (5783)
Policy (617)

Tag

Date

Today (3)
Last 7 days (23)
Last 30 days (122)
Last 365 days (1034)
2024 (971)
2023 (763)
2022 (1039)
2021 (978)
2020 (916)
2019 (778)
2018 (594)
2017 (730)
2016 (536)
2015 (551)
2014 (437)
2013 (361)
2012 (395)
2011 (404)
2010 (359)

Location

Africa (20)
Asia (601)
Australia (218)
California (68)
Canada (27)
China (12)
Europe (3022)
Florida (11)
Indiana (12)
Maryland (15)
Massachusetts (53)
Michigan (13)
Minnesota (5)
New Jersey (24)
New York (7)
North Carolina (6)
Northern California (36)
Pennsylvania (18)
South America (18)
Southern California (21)
Texas (7)
Washington State (5)

11,100 Results for "novo nordisk".

Sort By

GLP-1

Novo Nordisk Signs $285M GLP-1 Deal With Danish Neighbor Ascendis

In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon technology platform in an effort to find novel GLP-1 candidates with reduced dosing frequency.

November 4, 2024
·
1 min read
·
Annalee Armstrong
GLP-1

Novo Nordisk’s Ozempic Could Help Curb Cigarette Use in Diabetics: Study

Adding to growing evidence of its benefits beyond glucose control and weight loss, Novo Nordisk’s Ozempic could also potentially help diabetics quit smoking, according to new research.

July 30, 2024
·
2 min read
·
Tristan Manalac
GLP-1

Novo’s Wegovy Comparable to Madrigal’s Rezdiffra in Phase III MASH Trial: Analysts

In part 1 of the pivotal ESSENCE trial, Novo Nordisk’s weight loss drug Wegovy demonstrated “statistically significant and superior improvement” in liver fibrosis in patients with metabolic dysfunction–associated steatohepatitis.

November 1, 2024
·
3 min read
·
Heather McKenzie
GLP-1

Novo’s Semaglutide Linked to Reduced Alzheimer’s Risk in Real-World Study

Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in a study of medical records from 1 million patients.

October 24, 2024
·
2 min read
·
Annalee Armstrong
GLP-1

FDA Says All Doses of Novo’s Ozempic, Wegovy Now Available

Wednesday’s update to the regulator’s drug shortage database is good news for Novo Nordisk, which has struggled to keep up with demand for the blockbuster GLP-1 drugs.

October 31, 2024
·
2 min read
·
Tristan Manalac
Podcast

Lilly’s Q3 Miss, Novo’s MASH Win, CAR T’s Autoimmune Pivot, More

In our anniversary episode, we discuss a rare earnings miss for Eli Lilly, a pivotal metabolic dysfunction–associated steatohepatitis victory for Novo Nordisk’s Wegovy, growing excitement about CAR Ts for autoimmune disease and the ongoing controversy over HeLa cells.

November 6, 2024
·
1 min read
·
Heather McKenzie
Editorial

Why It’s OK to Talk About Catalent’s Pending Buyout by ‘Novo’

The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of Catalent currently under FTC review—ultimately send proceeds to the Novo Nordisk Foundation, one of the world’s largest charitable foundations.

October 24, 2024
·
6 min read
·
Jef Akst
Drug Development

Novo’s Ozempic Potentially Linked to Lower Opioid Overdose Risk in Diabetics

A retrospective cohort study of more than 33,000 patients with type 2 diabetes showed that Novo Nordisk’s GLP-1 may lower the risk of opioid overdose by 42% to up to 68%.

September 26, 2024
·
2 min read
·
Tristan Manalac
Policy

Novo’s Ozempic Seen as Shoo-In for Next Round of Medicare Price Negotiations

Novo Nordisk’s blockbuster type 2 diabetes medication is a sure bet for the list of the next 15 drugs whose Medicare prices will be negotiated in 2025 and go into effect in 2027, according to analysts and academics.

September 25, 2024
·
3 min read
·
Greg Slabodkin
Earnings

Novo Misses Overall Q3 Revenue Despite Beating Wegovy Sales Forecast, Narrows 2024 Outlook

Novo Nordisk’s total revenue in the third quarter missed analysts’ expectations but sales of weight loss drug Wegovy exceeded the consensus forecast. Still, the Danish drugmaker narrowed its full-year guidance for revenue and operating profit.

November 6, 2024
·
3 min read
·
Tristan Manalac

1 of 1,110

BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.

Explore
About
More

© 1985 - 2024 BioSpace.com. All rights reserved.

twitter
instagram
facebook
linkedin